GeneBioTech Co. Ltd (086060) — Cash Flow-to-Debt Ratio
GeneBioTech Co. Ltd (086060) has a Cash Flow-to-Debt Ratio of 0.18x as of September 2025, meaning its operating cash flow of ₩3.87 Billion could theoretically repay 0% of its total liabilities (₩21.41 Billion) in one year. See GeneBioTech Co. Ltd (086060) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
GeneBioTech Co. Ltd Cash Flow-to-Debt Ratio (2009–2024)
Historical debt coverage capacity for GeneBioTech Co. Ltd across 15 annual periods. Also explore how fast is GeneBioTech Co. Ltd growing its equity to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for GeneBioTech Co. Ltd (2009–2024)
Year-by-year debt coverage analysis for GeneBioTech Co. Ltd. For market capitalisation and broader financial context, see 086060 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.02x | ₩-463.87 Million | ₩21.02 Billion | ▼ -105.3% |
| 2023 | 0.42x | ₩7.37 Billion | ₩17.71 Billion | ▲ +307.1% |
| 2022 | -0.20x | ₩-3.68 Billion | ₩18.31 Billion | ▼ -16.1% |
| 2021 | -0.17x | ₩-2.84 Billion | ₩16.42 Billion | ▼ -218.3% |
| 2020 | 0.15x | ₩2.49 Billion | ₩17.04 Billion | ▲ +214.5% |
| 2019 | -0.13x | ₩-2.68 Billion | ₩21.00 Billion | ▼ -152.9% |
| 2018 | 0.24x | ₩5.96 Billion | ₩24.66 Billion | ▲ +306.3% |
| 2017 | 0.06x | ₩1.13 Billion | ₩19.05 Billion | ▼ -77.5% |
| 2016 | 0.26x | ₩5.31 Billion | ₩20.14 Billion | ▲ +106.3% |
| 2015 | 0.13x | ₩2.61 Billion | ₩20.37 Billion | ▲ +42.0% |
| 2014 | 0.09x | ₩2.15 Billion | ₩23.92 Billion | ▼ -4.4% |
| 2013 | 0.09x | ₩2.38 Billion | ₩25.25 Billion | ▼ -0.2% |
| 2011 | 0.09x | ₩2.53 Billion | ₩26.79 Billion | ▼ -9.4% |
| 2010 | 0.10x | ₩1.17 Billion | ₩11.18 Billion | ▼ -56.2% |
| 2009 | 0.24x | ₩2.68 Billion | ₩11.28 Billion | — |